Compare AES & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AES | CYTK |
|---|---|---|
| Founded | 1981 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 10.4B |
| IPO Year | 1996 | 2004 |
| Metric | AES | CYTK |
|---|---|---|
| Price | $14.68 | $76.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $15.29 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 10.6M | 3.1M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $12,233,000,000.00 | $13,368,000.00 |
| Revenue This Year | $5.22 | $7.37 |
| Revenue Next Year | $4.81 | $310.19 |
| P/E Ratio | $21.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.96 | $30.56 |
| 52 Week High | $17.65 | $80.20 |
| Indicator | AES | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 59.30 |
| Support Level | $14.01 | $59.07 |
| Resistance Level | $15.02 | $79.66 |
| Average True Range (ATR) | 0.07 | 2.64 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 85.23 | 60.95 |
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.